As chimeric antigen receptor T-cell therapies are becoming increasingly available in the armamentarium of the hematologist, there is an emerging need to monitor post-marketing safety.
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Isgrò, Valentina;Ferrajolo, Carmen;Trifirò, Gianluca
2022-01-01
Abstract
As chimeric antigen receptor T-cell therapies are becoming increasingly available in the armamentarium of the hematologist, there is an emerging need to monitor post-marketing safety.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
40264_2022_Article_1194.pdf
solo utenti autorizzati
Tipologia:
Versione dell'editore
Licenza:
Copyright dell'editore
Dimensione
1.08 MB
Formato
Adobe PDF
|
1.08 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
